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Table 1. Key features of hepatitis viruses [1, 2]
Hepatitis is major cause of  morbidity or mortality 
worldwide, particularly in the developing world. The 
major causes of  infective hepatitis are hepatitis viruses 
A, B, C, D or E. In the acute phase, there are no clinical 
features that can reliably differentiate between these 
viruses. Infection may be asymptomatic or can present as 
jaundice, fevers, abdominal pain, fatigue or vomiting. An 
acute hepatitis infection can last days to months, but can 
also cause fulminant liver failure.  
Some hepatitis virus infections become chronic, leading 
to cirrhosis and the development of  hepatocellular 
carcinoma. The difficulty in finding and treating these 
patients is that chronic infection is often asymptomatic 
until these endpoints develop. Co-infection with different 
hepatitis viruses or with HIV tends to worsen the 
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prognosis. Treatment decisions and regimes are complex 
and are beyond the scope of  this summary. National 
hepatitis guidelines are currently in development.
World Hepatitis Day took place on 28th July 2014 to 
raise awareness of  the disease and so in this article a table 
summarising the key features of  hepatitis virus infections 
is presented in Table 1.
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No, but hepatitis B 
vaccine effective
Yes, but not 
available globally
* High risk groups include men who have sex with men, sexual 
partners of  known infected individuals, individuals with multiple 
sexual partners, intravenous drug users, unscreened blood transfusion 
recipients, children of  known infected mothers, high prevalence areas.
Glossary 
HAV  Hepatitis A virus• 
HBcAg  Hepatitis B core antigen• 
HBeAg  Hepatitis B envelope antigen• 
HBsAg Hepatitis B surface antigen• 
HBV Hepatitis B virus• 
HCV Hepatitis C virus • 
HDV Hepatitis D virus• 
HEV Hepatitis E virus• 
IFN  Interferon• 
NAT Nucleic acid test• 
RBV Ribavarin• 
RT-PCR Reverse transcriptase polymerase chain reaction• 
